|100mcg 1inhaler||$57.99||$57.99 per inhaler|
|100mcg 3inhalers||$155.99||$52.00 per inhaler|
|100mcg 6inhalers||$279.99||$46.67 per inhaler|
Rhinocort is released in the form of an aerosol, capsules, powder, suspension and solution. The main drug component is budesonide.
Rhinocort is a medicinal glucocorticoid agent with a pronounced anti-inflammatory, antiallergic and immunostimulating effect, which allows treating bronchial asthma, which requires supporting therapy of GCS and chronic obstructive pulmonary disease.
This asthma inhaler is not prescribed if a patient is hypersensitive to its components. It is also not used in the treatment of children under 16 years of age.
With extreme caution, it is used to treat patients with an inactive form of tuberculosis, bacterial, fungal and viral lesions of the respiratory tract, during lactation and pregnancy.
Application during pregnancy and lactation
Rhinocort inhaler may be administered in the treatment of pregnant and lactating women, but only in the case, if the benefits of its use outweigh the possible risk to the newborn or fetus. At the moment, it is not known whether the drug penetrates into breast milk or not, and therefore, if it is prescribed to a nursing woman, it is necessary to stop lactation.
The doctor determines the duration of treatment and doses of budesonide independently, based on the symptoms and severity of the disease. The starting dose of the drug can vary from 1 to 2 mg per day, with maintenance treatment, the patient should receive from 0.5 to 4 mg per day. After the necessary therapeutic effect is achieved, the dose of the drug is recommended to be reduced to the minimum, which will allow maintaining the patient’s stable condition. In those cases when it is necessary to obtain a fast therapeutic effect, according to the doctor recommendations, the daily dose of the drug can be increased.
A single dose of this inhaler in high doses is not accompanied by the development of intoxication symptoms. However, long-term drug treatment in doses significantly higher than recommended, the patient may experience a systemic glucocorticosteroid effect of the type of hypercorticism, accompanied by suppression of adrenal function. If you identify symptoms of hypercortisolism, treatment with this medication is recommended to stop immediately.
The application of Rhinocort may be accompanied by the development of cough, dry mouth, voice hoarseness, dysphonia, irritation of the mucous of the mouth and pharynx, candidal stomatitis, dryness of the mucous membrane of the pharynx, headaches and nausea.
In rare cases, prolonged use of the drug in high doses can cause depletion of the adrenal cortex, hypertension and hyperglycemia.
Terms and conditions of storage
This drug must be stored in a cool, dark place. The preparation in the form of an aerosol must be protected from heat and open flame. The shelf life is 2 years.